Please use this identifier to cite or link to this item:
|Title:||Sustained remission of Lynch syndrome-associated metastatic adrenocortical carcinoma following checkpoint inhibitor therapy-associated multiorgan autoimmunity.|
|Authors:||Nevgi, Aditi;Klein, Oliver;Cheung, Ada S|
|Affiliation:||Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia|
Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Endocrinology Unit, Monash Health, Clayton, Australia
|Citation:||Clinical endocrinology 2020; online first: 25 May|
|Abstract:||Adrenocortical carcinoma (ACC) is a rare and aggressive tumour with limited treatment options for metastatic disease1 . Immunotherapy with checkpoint inhibition, in particular anti-programmed death receptor 1 (PD-1)/programmed death-ligand-1 (PD-L1) blockade has transformed the management of several malignancies. We describe prolonged remission of an ectopic-ACTH secreting refractory stage-IV ACC treated with anti-PD-1 antibody nivolumab combined with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.